India’s first intranasal vaccine for Covid gets DCGI approval
Representational Image | The English Post
Representational Image | The English Post
New Delhi | India’s first intranasal Covid vaccine by Bharat Biotech on Tuesday got the approval from the Drug Controller General of India for 18+ age group for restricted use in emergency situation.
Announcing the achievements, Union Health Minister Mansukh Mandaviya termed it a ‘big boost to India’s fight against Covid-19.
“Big Boost to India’s Fight Against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation,” Mandaviya tweeted.
In the subsequent tweet he said, “This step will further strengthen our collective fight against the pandemic.
“India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji’s leadership. With the science-driven approach & Sabka Prayas, we will defeat COVID-19”, he said.
IANS
The English Post is on Telegram, click to join for regular news update
SPONSORED CONTENT
